NetworkNewsBreaks – Oragenics, Inc. (NYSE Americ
Post# of 20
(Total Views: 110)
Posted On: 10/09/2024 4:50:20 PM
NetworkNewsBreaks – Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”).
“Our mission is to address significant unmet medical needs by developing cutting-edge therapies,” said Oragenics president Michael Redmond in the report. “There are over 3 million annual concussion occurrences in the U.S. and an estimated 69 million globally; however, it is believed that a substantial number, up to 50%, of cases go unreported. Given that there is still no FDA approval, and patients in need continue to face limited treatment options, the urgency to advance our efforts is greater than ever.”
NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://nnw.fm/OGEN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”).
“Our mission is to address significant unmet medical needs by developing cutting-edge therapies,” said Oragenics president Michael Redmond in the report. “There are over 3 million annual concussion occurrences in the U.S. and an estimated 69 million globally; however, it is believed that a substantial number, up to 50%, of cases go unreported. Given that there is still no FDA approval, and patients in need continue to face limited treatment options, the urgency to advance our efforts is greater than ever.”
NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://nnw.fm/OGEN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)